Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

MLA

Esposito Abate, Riziero, et al. “Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.” Cancers, vol. 11, no. 10, Oct. 2019, p. 1431. EBSCOhost, https://doi.org/10.3390/cancers11101431.

APA

Esposito Abate, R., Pasquale, R., Sacco, A., Piccirillo, M. C., Morabito, A., Bidoli, P., Finocchiaro, G., Chiari, R., Foltran, L., Buosi, R., Tiseo, M., Giannetta, L., Battiloro, C., Fasola, G., Romano, G., Ciuffreda, L., Frassoldati, A., de Marinis, F., Cappuzzo, F., & Normanno, N. (2019). Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. Cancers, 11(10), 1431. https://doi.org/10.3390/cancers11101431

Chicago

Esposito Abate, Riziero, Raffaella Pasquale, Alessandra Sacco, Maria Carmela Piccirillo, Alessandro Morabito, Paolo Bidoli, Giovanna Finocchiaro, et al. 2019. “Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.” Cancers 11 (10): 1431. doi:10.3390/cancers11101431.